Elevation Point Wealth Partners LLC Invests $589,000 in HealthEquity, Inc. $HQY

Elevation Point Wealth Partners LLC acquired a new stake in HealthEquity, Inc. (NASDAQ:HQY) in the second quarter, Holdings Channel reports. The firm acquired 6,525 shares of the company’s stock, valued at approximately $589,000.

Several other large investors have also bought and sold shares of the stock. Sivia Capital Partners LLC acquired a new position in HealthEquity during the 2nd quarter worth about $306,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of HealthEquity in the second quarter valued at about $4,747,000. Marshall Wace LLP bought a new position in shares of HealthEquity during the second quarter worth about $5,483,000. Amundi raised its position in shares of HealthEquity by 9.3% during the second quarter. Amundi now owns 30,203 shares of the company’s stock worth $3,059,000 after acquiring an additional 2,574 shares during the last quarter. Finally, Jump Financial LLC acquired a new position in shares of HealthEquity in the second quarter worth approximately $449,000. 99.55% of the stock is owned by institutional investors.

HealthEquity Stock Performance

NASDAQ:HQY opened at $105.40 on Tuesday. The company has a quick ratio of 3.44, a current ratio of 3.44 and a debt-to-equity ratio of 0.46. HealthEquity, Inc. has a twelve month low of $72.76 and a twelve month high of $107.62. The company has a fifty day moving average of $97.01 and a 200-day moving average of $87.37. The firm has a market capitalization of $8.81 billion, a P/E ratio of 39.48, a P/E/G ratio of 1.77 and a beta of 0.21.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings results on Thursday, May 28th. The company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.13. HealthEquity had a net margin of 17.25% and a return on equity of 14.75%. The business had revenue of $354.64 million during the quarter, compared to analysts’ expectations of $352.02 million. The firm’s revenue was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. As a group, sell-side analysts anticipate that HealthEquity, Inc. will post 3.92 EPS for the current year.

Insider Activity

In other HealthEquity news, Director Gayle Furgurson Wellborn sold 2,439 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $90.00, for a total value of $219,510.00. Following the transaction, the director owned 19,733 shares in the company, valued at approximately $1,775,970. This represents a 11.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Delano Ladd sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $90.00, for a total value of $675,000.00. Following the sale, the executive vice president owned 91,141 shares of the company’s stock, valued at approximately $8,202,690. This represents a 7.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 17,905 shares of company stock worth $1,651,280 in the last three months. Company insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on HQY shares. BTIG Research increased their target price on shares of HealthEquity from $110.00 to $115.00 and gave the company a “buy” rating in a research report on Friday, July 24th. KeyCorp restated an “overweight” rating on shares of HealthEquity in a research report on Tuesday, May 26th. Royal Bank Of Canada upped their price objective on shares of HealthEquity from $100.00 to $108.00 and gave the company an “outperform” rating in a research note on Wednesday, June 3rd. Barrington Research reissued an “outperform” rating and set a $110.00 target price on shares of HealthEquity in a research note on Friday, May 22nd. Finally, Weiss Ratings upgraded shares of HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, June 5th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $110.93.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.